Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1963 3
1967 1
1970 6
1971 1
1972 2
1973 3
1974 1
1975 3
1976 6
1977 4
1978 2
1979 4
1980 3
1981 6
1982 1
1983 9
1984 8
1985 9
1986 5
1987 16
1988 11
1989 8
1990 10
1991 13
1992 16
1993 14
1994 7
1995 10
1996 7
1997 14
1998 8
1999 13
2000 21
2001 10
2002 15
2003 22
2004 12
2005 23
2006 16
2007 11
2008 26
2009 16
2010 15
2011 17
2012 15
2013 20
2014 18
2015 26
2016 36
2017 33
2018 34
2019 58
2020 46
2021 70
2022 58
2023 51
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

824 results

Results by year

Filters applied: . Clear all
Page 1
Crossing the blood-brain barrier with nanoparticles.
Zhou Y, Peng Z, Seven ES, Leblanc RM. Zhou Y, et al. Among authors: leblanc rm. J Control Release. 2018 Jan 28;270:290-303. doi: 10.1016/j.jconrel.2017.12.015. Epub 2017 Dec 19. J Control Release. 2018. PMID: 29269142 Review.
Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit.
Lamontagne F, Masse MH, Menard J, Sprague S, Pinto R, Heyland DK, Cook DJ, Battista MC, Day AG, Guyatt GH, Kanji S, Parke R, McGuinness SP, Tirupakuzhi Vijayaraghavan BK, Annane D, Cohen D, Arabi YM, Bolduc B, Marinoff N, Rochwerg B, Millen T, Meade MO, Hand L, Watpool I, Porteous R, Young PJ, D'Aragon F, Belley-Cote EP, Carbonneau E, Clarke F, Maslove DM, Hunt M, Chassé M, Lebrasseur M, Lauzier F, Mehta S, Quiroz-Martinez H, Rewa OG, Charbonney E, Seely AJE, Kutsogiannis DJ, LeBlanc R, Mekontso-Dessap A, Mele TS, Turgeon AF, Wood G, Kohli SS, Shahin J, Twardowski P, Adhikari NKJ; LOVIT Investigators and the Canadian Critical Care Trials Group. Lamontagne F, et al. Among authors: leblanc r. N Engl J Med. 2022 Jun 23;386(25):2387-2398. doi: 10.1056/NEJMoa2200644. Epub 2022 Jun 15. N Engl J Med. 2022. PMID: 35704292 Clinical Trial.
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Dimopoulos MA, et al. Among authors: leblanc r. N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762. N Engl J Med. 2018. PMID: 30403938 Clinical Trial.
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Dimopoulos MA, et al. Among authors: leblanc r. J Clin Oncol. 2023 Jan 20;41(3):568-578. doi: 10.1200/JCO.21.02815. Epub 2022 Aug 12. J Clin Oncol. 2023. PMID: 35960908 Free PMC article. Clinical Trial.
Cutaneous B-Cell Lymphoma.
Goyal A, LeBlanc RE, Carter JB. Goyal A, et al. Among authors: leblanc re. Hematol Oncol Clin North Am. 2019 Feb;33(1):149-161. doi: 10.1016/j.hoc.2018.08.006. Hematol Oncol Clin North Am. 2019. PMID: 30497672 Review.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Lonial S, et al. Among authors: leblanc r. Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7. Lancet. 2016. PMID: 26778538 Clinical Trial.
Structure-Property-Activity Relationships in Carbon Dots.
Zhou Y, Zhang W, Leblanc RM. Zhou Y, et al. Among authors: leblanc rm. J Phys Chem B. 2022 Dec 29;126(51):10777-10796. doi: 10.1021/acs.jpcb.2c06856. Epub 2022 Nov 17. J Phys Chem B. 2022. PMID: 36395361 Review.
Bone Tissue Engineering via Carbon-Based Nanomaterials.
Peng Z, Zhao T, Zhou Y, Li S, Li J, Leblanc RM. Peng Z, et al. Among authors: leblanc rm. Adv Healthc Mater. 2020 Mar;9(5):e1901495. doi: 10.1002/adhm.201901495. Epub 2020 Jan 24. Adv Healthc Mater. 2020. PMID: 31976623 Review.
Carbon dot composites for bioapplications: a review.
Wu J, Chen G, Jia Y, Ji C, Wang Y, Zhou Y, Leblanc RM, Peng Z. Wu J, et al. Among authors: leblanc rm. J Mater Chem B. 2022 Feb 9;10(6):843-869. doi: 10.1039/d1tb02446a. J Mater Chem B. 2022. PMID: 35060567 Review.
Downregulation of stromal syntenin sustains AML development.
Leblanc R, Ghossoub R, Goubard A, Castellano R, Fares J, Camoin L, Audebert S, Balzano M, Bou-Tayeh B, Fauriat C, Vey N, Garciaz S, Borg JP, Collette Y, Aurrand-Lions M, David G, Zimmermann P. Leblanc R, et al. EMBO Mol Med. 2023 Nov 8;15(11):e17570. doi: 10.15252/emmm.202317570. Epub 2023 Oct 11. EMBO Mol Med. 2023. PMID: 37819151 Free PMC article.
824 results